Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Pertuzumab
Related studies linked through entity extraction aliases.
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
- Status
- UNKNOWN
- Phase
- PHASE2
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
- Status
- COMPLETED
- Phase
- PHASE2
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Status
- TERMINATED
- Phase
- PHASE1
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE3
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3